Olaparib Oral Product

DRUG3 trials

Sponsors

Duke University, Leiden University Medical Center, National Cancer Institute, Naples

Conditions

BRCA1 MutationBRCA2 MutationHomologous Recombination DeficiencyOvarian CancerOvarian Neoplasm EpithelialTriple Negative Breast Cancer

Phase 2

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

CompletedNCT03167619

Duke UniversityTriple Negative Breast Cancer

Start: 2018-10-04End: 2022-06-30Updated: 2022-09-13

Functional Analysis of BRCAness

TerminatedNCT04780945

Leiden University Medical CenterBRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency +1

Start: 2019-01-21End: 2024-12-31Updated: 2026-02-17

MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer

RecruitingNCT05233982

National Cancer Institute, NaplesOvarian Cancer

Start: 2021-12-09End: 2026-01-31Target: 200Updated: 2023-03-24

Related Papers

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Clinical Cancer Research2024-01-1824 citations

Abstract PD11-12: PD11-12 DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC)

Cancer Research2023-03-015 citations

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).

Journal of Clinical Oncology2019-05-2013 citations

Abstract OT3-04-02: The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)

Cancer Research2018-02-153 citations